AIM News and Press, AIM ImmunoTech Inc. From 01/17/23

A Florida-based %Biotech company captured the attention of the trading community on Tuesday after it was announced that it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca, according to today’s press release. This news...

AIM ImmunoTech ( NYSE: AIM ) jumped ~17% in the morning hours Tuesday after announcing a collaboration with Erasmus University Medical Center and AstraZeneca ( AZN ) for an investigator-initiated study for its lead asset Ampligen (rintatolimod). According to the agreement, Era...

Penny Stocks + News = ? It’s a new week of the New Year, and traders have high hopes for a January rebound. The exciting part about penny stocks , in particular, is they tend to move independently of broader market trends. That is to say, when the stock market is down, there’...

OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseas...

- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...

OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral...

OCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira...

OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseas...

Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British Society for Immun...

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseas...